Category: Parkinson’s News

Students work on their thesis for weeks, months, sometimes years. Once completed, their work is often relegated to a dusty drawer. The Thesis Tales column is devoted to highlighting student research. In episode 3: Femke Aminetzah (21, Bachelor’s in Artificial Intelligence) investigated the best way to reduce motor symptoms in parkinson’s patients using AI.

Nancy Schexnaider, a hospice social worker from Vermilion Parish, shares why her Parkinson’s diagnosis in 2022 was, “the best thing that ever happened to her.”

University Hospitals and Cleveland Clinic published a peer-reviewed article this month detailing ways to reduce preventable harm during Parkinson’s patients’ hospital stays.

Wrexham player ratings vs Crewe 1️⃣-🔟

Wearable sensor data combined with machine learning predicts fall risk in Parkinson’s patients, enhancing preventive care and clinical outcomes over five years.

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson’s disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with ea

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently lacking effective cognitive therapies. Parkinson’s disease is a neurological disorder primarily k

Michael J. Fox has reportedly broken more bones than his own stuntman, Charlie Croughwell.Fox, who was diagnosed with Parkinson’s disease in 1991, has faced increasing physical challenges.Speaking with Metro, Croughwell, who…

Detroit Lions punter Jack Fox is set to honor the Kirk Gibson Foundation for Parkinson’s as part of the “My Cause My Cleats” initiative.

Harvard researchers studying neurodegenerative disorders see a potential culprit — and treatment target — where you might not have guessed.